{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Santos Bravo M"],"funding":["CIBER Enfermedades Infecciosas","Gilead Sciences"],"pagination":["e0244822"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9769853"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(6)"],"pubmed_abstract":["Remdesivir (RDV) was the first antiviral drug approved by the FDA to treat severe coronavirus disease-2019 (COVID-19) patients. RDV inhibits SARS-CoV-2 replication by stalling the non structural protein 12 (nsp12) subunit of the RNA-dependent RNA polymerase (RdRp). No evidence of global widespread RDV-resistance mutations has been reported, however, defining genetic pathways to RDV resistance and determining emergent mutations prior and subsequent antiviral therapy in clinical settings is necessary. This study identified 57/149 (38.3%) patients who did not respond to one course (5-days) (<i>n</i> = 36/111, 32.4%) or prolonged (5 to 20 days) (<i>n</i> = 21/38, 55.3%) RDV therapy by subgenomic RNA detection. Genetic variants in the <i>nsp12</i> gene were detected in 29/49 (59.2%) non respond"],"journal":["Microbiology spectrum"],"pubmed_title":["Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir."],"pmcid":["PMC9769853"],"funding_grant_id":["IN-ES-540-6089","CB21/13/00081"],"pubmed_authors":["Sanchez Palomino S","Villanueva JL","Puerta P","Alonso R","Vergara A","Mosquera Gutierrez MDM","Rodriguez C","Vila J","Diez-Fuertes F","Castro P","Sanzo Machuca A","Simarro Redon A","Rubio E","Cuesta G","Hurtado JC","Soriano A","Marcos MA","Martinez MJ","Alcami J","Soria D","Tuset M","Fernandez Aviles F","Bodro M","Garcia C","Santos Bravo M"],"additional_accession":[]},"is_claimable":false,"name":"Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.","description":"Remdesivir (RDV) was the first antiviral drug approved by the FDA to treat severe coronavirus disease-2019 (COVID-19) patients. RDV inhibits SARS-CoV-2 replication by stalling the non structural protein 12 (nsp12) subunit of the RNA-dependent RNA polymerase (RdRp). No evidence of global widespread RDV-resistance mutations has been reported, however, defining genetic pathways to RDV resistance and determining emergent mutations prior and subsequent antiviral therapy in clinical settings is necessary. This study identified 57/149 (38.3%) patients who did not respond to one course (5-days) (<i>n</i> = 36/111, 32.4%) or prolonged (5 to 20 days) (<i>n</i> = 21/38, 55.3%) RDV therapy by subgenomic RNA detection. Genetic variants in the <i>nsp12</i> gene were detected in 29/49 (59.2%) non respond","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T21:31:04.738Z","creation":"2024-12-04T05:13:01.667Z"},"accession":"S-EPMC9769853","cross_references":{"pubmed":["36354320"],"doi":["10.1128/spectrum.02448-22"]}}